These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16603720)

  • 21. Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice.
    Berti JA; Salerno AG; Bighetti EJ; Casquero AC; Boschero AC; Oliveira HC
    APMIS; 2005 Jan; 113(1):37-44. PubMed ID: 15676013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.
    Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 2001 Feb; 42(2):241-8. PubMed ID: 11181754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
    Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/ApoCI-knocked out mice.
    Gautier T; Masson D; Jong MC; Duverneuil L; Le Guern N; Deckert V; Pais de Barros JP; Dumont L; Bataille A; Zak Z; Jiang XC; Tall AR; Havekes LM; Lagrost L
    J Biol Chem; 2002 Aug; 277(35):31354-63. PubMed ID: 12070157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice.
    Kako Y; Massé M; Huang LS; Tall AR; Goldberg IJ
    J Lipid Res; 2002 Jun; 43(6):872-7. PubMed ID: 12032161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes.
    Masson D; Pais de Barros JP; Zak Z; Gautier T; Le Guern N; Assem M; Chisholm JW; Paterniti JR; Lagrost L
    J Lipid Res; 2006 Feb; 47(2):356-65. PubMed ID: 16282639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins.
    Lie J; de Crom R; van Gent T; van Haperen R; Scheek L; Sadeghi-Niaraki F; van Tol A
    J Lipid Res; 2004 May; 45(5):805-11. PubMed ID: 14993244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits.
    Sugano M; Makino N; Sawada S; Otsuka S; Watanabe M; Okamoto H; Kamada M; Mizushima A
    J Biol Chem; 1998 Feb; 273(9):5033-6. PubMed ID: 9478952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profound induction of hepatic cholesteryl ester transfer protein transgene expression in apolipoprotein E and low density lipoprotein receptor gene knockout mice. A novel mechanism signals changes in plasma cholesterol levels.
    Masucci-Magoulas L; Plump A; Jiang XC; Walsh A; Breslow JL; Tall AR
    J Clin Invest; 1996 Jan; 97(1):154-61. PubMed ID: 8550828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice.
    Föger B; Chase M; Amar MJ; Vaisman BL; Shamburek RD; Paigen B; Fruchart-Najib J; Paiz JA; Koch CA; Hoyt RF; Brewer HB; Santamarina-Fojo S
    J Biol Chem; 1999 Dec; 274(52):36912-20. PubMed ID: 10601244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia.
    Guérin M; Bruckert E; Dolphin PJ; Chapman MJ
    Eur J Clin Invest; 1996 Jun; 26(6):485-94. PubMed ID: 8817163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans.
    Grass DS; Saini U; Felkner RH; Wallace RE; Lago WJ; Young SG; Swanson ME
    J Lipid Res; 1995 May; 36(5):1082-91. PubMed ID: 7658156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
    Le Goff W; Guerin M; Chapman MJ
    Pharmacol Ther; 2004 Jan; 101(1):17-38. PubMed ID: 14729390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein E enhances lipid exchange between lipoproteins mediated by cholesteryl ester transfer protein.
    Kinoshita M; Arai H; Fukasawa M; Watanabe T; Tsukamoto K; Hashimoto Y; Inoue K; Kurokawa K; Teramoto T
    J Lipid Res; 1993 Feb; 34(2):261-8. PubMed ID: 8429260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice.
    Masucci-Magoulas L; Moulin P; Jiang XC; Richardson H; Walsh A; Breslow JL; Tall A
    J Clin Invest; 1995 Apr; 95(4):1587-94. PubMed ID: 7706465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo effects of CETP inhibitory peptides in hypercholesterolemic rabbit and cholesteryl ester transfer protein-transgenic mice.
    Cho KH; Shin YW; Choi MS; Bok SH; Jang SH; Park YB
    J Biochem Mol Biol; 2002 Mar; 35(2):172-7. PubMed ID: 12297026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion.
    Harada LM; Amigo L; Cazita PM; Salerno AG; Rigotti AA; Quintão EC; Oliveira HC
    Atherosclerosis; 2007 Apr; 191(2):313-8. PubMed ID: 16806230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.
    Ambrosch A; Mühlen I; Kopf D; Augustin W; Dierkes J; König W; Luley C; Lehnert H
    Diabetes Care; 1998 Dec; 21(12):2077-84. PubMed ID: 9839097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.